Benzinga · Oct 12, 2026
Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6
Leerink Partners analyst Will Soghikian assumes Equillium (NASDAQ:EQ) with a Outperform rating and announces Price Target of $6.
EQ
NASDAQ · EQ
Equillium, Inc. Common Stock
Healthcare · Biotechnology
$1.25
Up+$0.02 (+1.63%)
Updated Oct 27, 2026, 10:40 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 47.6M
- P/E ratio
- -3.58
- Dividend yield
- 0.00%
- 52-week range
- $0.76 – $3.54
- Volume
- 210.79K
- Avg. volume
- 570.19K
Price performance · EQ
EQ price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
EQ closed at $1.25 after 21 trading sessions, down 25.60% for the selected period.
- Last close
- $1.25
- Period change
- -25.60%
- Period low
- $1.19
- Period high
- $1.68
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $1.20 | $1.25 | $1.17 | $1.25 | 210.79K |
| Oct 23, 2026 | $1.25 | $1.2935 | $1.18 | $1.23 | 315.66K |
| Oct 22, 2026 | $1.40 | $1.4199 | $1.23 | $1.27 | 315.47K |
| Oct 21, 2026 | $1.40 | $1.51 | $1.385 | $1.42 | 442.54K |
| Oct 20, 2026 | $1.25 | $1.43 | $1.24 | $1.38 | 774.54K |
| Oct 19, 2026 | $1.22 | $1.2907 | $1.16 | $1.24 | 3.19M |
| Oct 16, 2026 | $1.32 | $1.35 | $1.185 | $1.19 | 466.79K |
| Oct 15, 2026 | $1.30 | $1.38 | $1.28 | $1.32 | 510.93K |
| Oct 14, 2026 | $1.32 | $1.38 | $1.30 | $1.30 | 263.78K |
| Oct 13, 2026 | $1.50 | $1.50 | $1.32 | $1.32 | 397.77K |
| Oct 12, 2026 | $1.42 | $1.51 | $1.39 | $1.50 | 383.75K |
| Oct 9, 2026 | $1.45 | $1.46 | $1.38 | $1.41 | 522K |
| Oct 8, 2026 | $1.41 | $1.46 | $1.34 | $1.44 | 645.03K |
| Oct 7, 2026 | $1.41 | $1.425 | $1.35 | $1.39 | 343.32K |
| Oct 6, 2026 | $1.39 | $1.47 | $1.37 | $1.42 | 393.62K |
| Oct 5, 2026 | $1.37 | $1.455 | $1.30 | $1.45 | 795.62K |
| Oct 2, 2026 | $1.55 | $1.60 | $1.375 | $1.41 | 934.79K |
| Oct 1, 2026 | $1.67 | $1.67 | $1.525 | $1.54 | 529.4K |
| Sep 30, 2026 | $1.63 | $1.655 | $1.58 | $1.625 | 3.1M |
| Sep 29, 2026 | $1.68 | $1.72 | $1.61 | $1.62 | 316.29K |
| Sep 28, 2026 | $1.65 | $1.715 | $1.63 | $1.68 | 241.73K |
Latest EQ news
The latest Smart Investors Daily articles mentioning EQ.
Stock researchCompany · Overview
Company
Market Activity
Research & News
EQ research
Overview
Company profile and research snapshot.
Company profile
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $1.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 4, 2026 | Roth Capital | Buy | — |
| Jul 13, 2026 | Piper Sandler | Overweight | — |
| Jun 2, 2026 | Roth Capital | Buy | — |
| May 28, 2026 | Roth Capital | Buy | — |
| May 28, 2026 | Leerink Partners | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 6, 2026
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
New preclinical data further characterizes EQ504’s coordinated effects across epithelial and immune compartments in intestinal inflammationLA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in a poster at the 50th Anniversary La Jolla Immunology Conference, taking place October
Yahoo · Oct 5, 2026
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of EQ504 in healthy subjects LA JOLLA, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders,
Yahoo · Sep 29, 2026
Equillium Announces Poster Presentations at the 7th International AHR Conference
New preclinical data further characterize EQ504’s effects on epithelial barrier repair and immune regulationLA JOLLA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in two posters at the 7th International AHR Conference, taking place September 29 to October 2, 2026, in Porto, Portug
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
